Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.42 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2036709 | 0.83 | TSHR (0.62) | TSHRCYP3A4GPR35HCAR3KDM4E | |
| SCHEMBL7041286 | 0.83 | TSHR (0.53) | TSHRCYP3A4GPR35HCAR3KDM4E | |
| SCHEMBL10936850 | 0.81 | TSHR (0.55) | TSHRCYP3A4GPR35HCAR3KDM4E | |
| SCHEMBL27768184 | 0.78 | TSHR (0.51) | TSHRCYP3A4GPR35HCAR3KDM4E | |
| SCHEMBL11613863 | 0.78 | TSHR (0.51) | TSHRCYP3A4GPR35HCAR3KDM4E | |
| SCHEMBL9769601 | 0.78 | ALDH1A1 (0.54) | TSHRCYP3A4GPR35HCAR3KDM4E | |
| SCHEMBL7328486 | 0.77 | TSHR (0.55) | TSHRCYP3A4GPR35HCAR3KDM4E | |
| SCHEMBL29320803 | 0.77 | TSHR (0.55) | TSHRCYP3A4GPR35HCAR3KDM4E | |
| SCHEMBL13999624 | 0.76 | GPR35 (0.69) | TSHRCYP3A4GPR35KDM4EPOLB | |
| SCHEMBL18676266 | 0.76 | ALDH1A1 (0.55) | TSHRCYP3A4GPR35HCAR3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108545-A1 | Trioxane Monomers and Dimers | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108545-A1 | Trioxane Monomers and Dimers | CDK10, TMSB10, CASP10 | TSHR 1327/4885CYP3A4 561/4885GPR35 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.